Target Price | $7.61 |
Price | $1.18 |
Potential |
544.67%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Gossamer Bio, Inc. 2026 .
The average Gossamer Bio, Inc. target price is $7.61.
This is
544.67%
register free of charge
$15.00
1,171.19%
register free of charge
$1.25
5.93%
register free of charge
|
|
A rating was issued by 9 analysts: 7 Analysts recommend Gossamer Bio, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Gossamer Bio, Inc. stock has an average upside potential 2026 of
544.67%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 114.70 | 24.43 |
78.71% | ||
EBITDA Margin | -48.62% | -594.49% |
1,122.66% | ||
Net Margin | -49.52% | -615.25% |
1,142.31% |
9 Analysts have issued a sales forecast Gossamer Bio, Inc. 2025 . The average Gossamer Bio, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Gossamer Bio, Inc. EBITDA forecast 2025. The average Gossamer Bio, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Gossamer Bio, Inc. Analysts have issued a net profit forecast 2025. The average Gossamer Bio, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.25 | -0.66 |
78.81% | 164.00% | |
P/E | negative | |
EV/Sales | 8.72 |
4 Analysts have issued a Gossamer Bio, Inc. forecast for earnings per share. The average Gossamer Bio, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Gossamer Bio, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Goldman Sachs |
Locked
➜
Locked
|
Locked | May 16 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | May 16 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
Analyst Rating | Date |
---|---|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 16 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
May 16 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 18 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
Mar 14 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 30 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.